S&P 500   5,107.36 (+0.22%)
DOW   38,979.23 (-0.04%)
QQQ   441.72 (+0.62%)
AAPL   179.04 (-0.95%)
MSFT   412.17 (-0.36%)
META   499.26 (+1.86%)
GOOGL   137.69 (-0.56%)
AMZN   177.02 (+0.15%)
TSLA   199.80 (-1.03%)
NVDA   802.68 (+1.46%)
NIO   5.74 (-0.17%)
AMD   199.25 (+3.49%)
BABA   74.68 (+0.88%)
T   16.92 (-0.06%)
F   12.54 (+0.80%)
MU   93.85 (+3.58%)
CGC   3.15 (-4.26%)
GE   158.18 (+0.82%)
DIS   111.99 (+0.37%)
AMC   4.34 (+0.46%)
PFE   26.59 (+0.11%)
PYPL   61.17 (+1.38%)
XOM   105.65 (+1.08%)
S&P 500   5,107.36 (+0.22%)
DOW   38,979.23 (-0.04%)
QQQ   441.72 (+0.62%)
AAPL   179.04 (-0.95%)
MSFT   412.17 (-0.36%)
META   499.26 (+1.86%)
GOOGL   137.69 (-0.56%)
AMZN   177.02 (+0.15%)
TSLA   199.80 (-1.03%)
NVDA   802.68 (+1.46%)
NIO   5.74 (-0.17%)
AMD   199.25 (+3.49%)
BABA   74.68 (+0.88%)
T   16.92 (-0.06%)
F   12.54 (+0.80%)
MU   93.85 (+3.58%)
CGC   3.15 (-4.26%)
GE   158.18 (+0.82%)
DIS   111.99 (+0.37%)
AMC   4.34 (+0.46%)
PFE   26.59 (+0.11%)
PYPL   61.17 (+1.38%)
XOM   105.65 (+1.08%)
S&P 500   5,107.36 (+0.22%)
DOW   38,979.23 (-0.04%)
QQQ   441.72 (+0.62%)
AAPL   179.04 (-0.95%)
MSFT   412.17 (-0.36%)
META   499.26 (+1.86%)
GOOGL   137.69 (-0.56%)
AMZN   177.02 (+0.15%)
TSLA   199.80 (-1.03%)
NVDA   802.68 (+1.46%)
NIO   5.74 (-0.17%)
AMD   199.25 (+3.49%)
BABA   74.68 (+0.88%)
T   16.92 (-0.06%)
F   12.54 (+0.80%)
MU   93.85 (+3.58%)
CGC   3.15 (-4.26%)
GE   158.18 (+0.82%)
DIS   111.99 (+0.37%)
AMC   4.34 (+0.46%)
PFE   26.59 (+0.11%)
PYPL   61.17 (+1.38%)
XOM   105.65 (+1.08%)
S&P 500   5,107.36 (+0.22%)
DOW   38,979.23 (-0.04%)
QQQ   441.72 (+0.62%)
AAPL   179.04 (-0.95%)
MSFT   412.17 (-0.36%)
META   499.26 (+1.86%)
GOOGL   137.69 (-0.56%)
AMZN   177.02 (+0.15%)
TSLA   199.80 (-1.03%)
NVDA   802.68 (+1.46%)
NIO   5.74 (-0.17%)
AMD   199.25 (+3.49%)
BABA   74.68 (+0.88%)
T   16.92 (-0.06%)
F   12.54 (+0.80%)
MU   93.85 (+3.58%)
CGC   3.15 (-4.26%)
GE   158.18 (+0.82%)
DIS   111.99 (+0.37%)
AMC   4.34 (+0.46%)
PFE   26.59 (+0.11%)
PYPL   61.17 (+1.38%)
XOM   105.65 (+1.08%)

United Therapeutics (UTHR) Stock Price, News & Analysis

$232.24
+6.60 (+2.93%)
(As of 10:10 AM ET)
Today's Range
$227.00
$232.24
50-Day Range
$210.76
$231.04
52-Week Range
$204.44
$261.54
Volume
61,489 shs
Average Volume
350,166 shs
Market Capitalization
$10.93 billion
P/E Ratio
11.71
Dividend Yield
N/A
Price Target
$292.80

United Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
29.8% Upside
$292.80 Price Target
Short Interest
Healthy
2.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.08mentions of United Therapeutics in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$9.34 M Sold Last Quarter
Proj. Earnings Growth
5.41%
From $22.90 to $24.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

9th out of 957 stocks

Pharmaceutical Preparations Industry

3rd out of 440 stocks


UTHR stock logo

About United Therapeutics Stock (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock Price History

UTHR Stock News Headlines

Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
5 Fastest Growing Biotech Companies in the US
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
United Therapeutics Q4 Net Income Rises
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/01/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
1,168
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$292.80
High Stock Price Target
$330.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+29.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$984.80 million
Pretax Margin
54.75%

Debt

Sales & Book Value

Annual Sales
$2.33 billion
Cash Flow
$21.93 per share
Book Value
$127.18 per share

Miscellaneous

Free Float
41,177,000
Market Cap
$10.62 billion
Optionable
Optionable
Beta
0.52

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














UTHR Stock Analysis - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price target for 2024?

11 Wall Street research analysts have issued 12-month price targets for United Therapeutics' stock. Their UTHR share price targets range from $215.00 to $330.00. On average, they predict the company's share price to reach $292.80 in the next year. This suggests a possible upside of 29.8% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2024?

United Therapeutics' stock was trading at $219.89 at the beginning of the year. Since then, UTHR shares have increased by 2.6% and is now trading at $225.64.
View the best growth stocks for 2024 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. The biotechnology company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a trailing twelve-month return on equity of 17.72% and a net margin of 42.31%. The business's revenue for the quarter was up 25.1% on a year-over-year basis. During the same period last year, the company posted $2.67 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.95%), Avoro Capital Advisors LLC (6.08%), Dimensional Fund Advisors LP (1.20%), Nuveen Asset Management LLC (1.05%), Norges Bank (0.97%) and Palo Alto Investors LP (0.84%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UTHR) was last updated on 3/1/2024 by MarketBeat.com Staff